| Lauren Wiegman, PT, DPT, CKTP | |
|
3000 Fairway Dr, Altoona, PA 16602-4472 | |
| (814) 231-2101 | |
| (814) 231-8569 |
| Full Name | Lauren Wiegman |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 6 Years |
| Location | 3000 Fairway Dr, Altoona, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710535232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | PT028109 (Pennsylvania) | Secondary |
| 225100000X | Physical Therapist | PT028109 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Orthopedics Center, Ltd | 4284528621 | 54 |
News Archive
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments.
Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
› Verified 3 days ago
| Entity Name | University Orthopedics Center, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770500415 PECOS PAC ID: 4284528621 Enrollment ID: O20040209000496 |
News Archive
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments.
Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
› Verified 3 days ago
| Entity Name | Blair Regenerative Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629624689 PECOS PAC ID: 1951733872 Enrollment ID: O20191114002845 |
News Archive
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments.
Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Wiegman, PT, DPT, CKTP 3000 Fairway Dr, Altoona, PA 16602-4472 Ph: (814) 231-2101 | Lauren Wiegman, PT, DPT, CKTP 3000 Fairway Dr, Altoona, PA 16602-4472 Ph: (814) 231-2101 |
News Archive
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments.
Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
› Verified 3 days ago